Is the Market Bullish or Bearish on Recursion Pharmaceuticals Inc?

Recursion Pharmaceuticals Inc's (NYSE: RXRX) short interest as a percent of float has fallen 15.85% since its last report.
Labmate Online

ELRIG 2025: Recursion's high content imaging and AI platform promises to reboot efficiency in drug discovery

At ELRIG’s 2025 meeting in GSK’s Stevenage campus, Recursion’s Executive Director of Computational Biology, Dr. Kelly ...
IEEE

Data-Driven Mean-Corrected Recursive Estimation-Based Optimal DER Dispatch for Distribution System Voltage Control

Abstract: Recent advances in smart inverters offer opportunities to mitigate adverse grid impacts caused by high penetrations of distributed photovoltaics (PV) in distribution grids, such as voltage ...
Visual Studio Magazine

Decision Tree Regression from Scratch with Pointers Using C#

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

Is Recursion Pharmaceuticals a Meme Stock?

Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...

Recursion Pharmaceuticals: What To Make Of This AI-Based Drug Discovery Leader?

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Recursion’s Incoming CEO Needs To Prove That AI Drug Development Can Pay Off

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
C&EN

Data-Driven Recursive Kinetic Modeling for Fenton Reaction

State Key Laboratory of Advanced Environmental Technology, Department of Environmental Science and Engineering, University of Science and Technology of China, Hefei 230026, China ...